Skip to content
Sunday, November 22, 2026 Market moodBearish−37.1
Sign in
GlideslopeGlideslopeGlideslope AI-powered market news
GlideslopeGlideslopeGlideslope
Breaking
COINTELEGRAPH South Korean exchanges halt CYBER transfers amid suspected bridge exploit Neutral BBC BUSINESS MP criticises Guernsey and Jersey company ownership register plans Bearish BBC BUSINESS Italian jeweller and businessman Paolo Bulgari dies aged 89 Bearish NEW YORK POST BUSINESS Paolo Bulgari, Italian jeweler who turned family business into global luxury brand, dead … Bearish CNBC TOP STORIES Quantum computing’s first real-world payoff may come in energy, not drug discovery Neutral COINTELEGRAPH Chainflip confirms $12M hack, offers attacker 10% bounty Bearish FOREIGN POLICY Ronald Reagan Changed His Chief of Staff After a Midterm Trouncing, Too Neutral CBS NEWS Kansas City Current capture first NWSL trophy Strong Bullish FOX NEWS US Three killed, one injured in shooting at Ohio baby shower, police say Pessimistic FOX NEWS US Florida man sentenced to death for 'cold, calculated' murder of attorney whose body was n… Pessimistic COINTELEGRAPH South Korean exchanges halt CYBER transfers amid suspected bridge exploit Neutral BBC BUSINESS MP criticises Guernsey and Jersey company ownership register plans Bearish BBC BUSINESS Italian jeweller and businessman Paolo Bulgari dies aged 89 Bearish NEW YORK POST BUSINESS Paolo Bulgari, Italian jeweler who turned family business into global luxury brand, dead … Bearish CNBC TOP STORIES Quantum computing’s first real-world payoff may come in energy, not drug discovery Neutral COINTELEGRAPH Chainflip confirms $12M hack, offers attacker 10% bounty Bearish FOREIGN POLICY Ronald Reagan Changed His Chief of Staff After a Midterm Trouncing, Too Neutral CBS NEWS Kansas City Current capture first NWSL trophy Strong Bullish FOX NEWS US Three killed, one injured in shooting at Ohio baby shower, police say Pessimistic FOX NEWS US Florida man sentenced to death for 'cold, calculated' murder of attorney whose body was n… Pessimistic
Story 07 of 9
  1. 01SpaceX Swings to Profit as Merger Speculation With Tesla Heats Up
  2. 02Oil Surges to Five-Month High as Middle East Tensions Persist
  3. 03Google Cloud Outage Cripples UK Banks; Revolut Hit Hardest
  4. 04U.S. Bans DeepSeek From Federal Civilian Agencies Amid AI-China Tensions
  5. 05Walmart Bundles Walmart+ and Sam's Club to Challenge Amazon Prime and Costco
  6. 06Trump's 50% Canadian Tariffs Face Legal Challenge Over Executive Authority
  7. 07Eli Lilly Hits Record Valuation on Obesity Drug Momentum and Strong Earnings Outlook
  8. 08Saudi Arabia Cancels Investment Summit as Houthi Attacks Escalate
  9. 09Amazon and Google Team Up to Break Nvidia's PyTorch Dominance
Healthcare

Eli Lilly Hits Record Valuation on Obesity Drug Momentum and Strong Earnings Outlook

Eli Lilly Hits Record Valuation on Obesity Drug Momentum and Strong Earnings Outlook

What’s happening

Eli Lilly (LLY) stock hit a new record as the company's market cap surpassed Berkshire Hathaway, buoyed by positive Phase 3 pediatric ulcerative colitis data and European regulatory progress on its oral obesity pill Foundayo. Goldman Sachs expects Lilly to beat Q3 earnings estimates and raise guidance, citing stronger-than-expected drug uptake.

Market impact

Lilly's ascent reflects investor conviction in the obesity drug market's scale and durability. Peers Novo Nordisk and Amgen also rallied on the news. The stock's valuation premium now prices in sustained 10%+ annual growth; any earnings miss or competitive pressure would trigger sharp correction.

Broader implications

Obesity drugs are reshaping global healthcare economics and pharma valuations. Lilly's dominance in this category—combined with its diversified pipeline—positions it as a defensive mega-cap in a volatile market, but valuation risk is material if growth decelerates.

Sources (3)

The articles Pulse read to write this story
  1. Eli Lilly Rises 4% While Foundayo Nears European Approval; Amgen and Novo Nordisk Edge Higher
  2. LLY Stock Hits New Record, Eli Lilly Valuation Pushes Past Berkshire Hathaway Ahead Of Q3 Earnings
  3. If Eli Lilly Grows At 10% a Year, Here's What $1,000 Becomes By 2030

Written by Pulse AI from the articles above. Always check the original reporting before acting on it.

● MACRO ANALYST

Apex+

Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.

LOG IN / SUBSCRIBE